Date: 2013-07-23
Type of information: IPO
Company: Sage Therapeutics (USA - MA)
Investors:
Amount: $103.5 million
Funding type: IPO
Planned used:
Others: * On July 23, 2014, Sage Therapeutics has announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $18.00 per share, before underwriting discounts, which includes the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares of common stock. Including the exercise of the over-allotment, SAGE has sold a total of 5,750,000 shares of its common stock, which represents a total capital raise of $103.5 million, before underwriting discounts. The company\'s common stock is listed on The NASDAQ Global Market under the symbol \"SAGE.\" J.P. Morgan and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Leerink Swan is acting as lead manager and Canaccord Genuity Inc. is acting as co-manager.
Therapeutic area: CNS diseases
